Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Hematopoiesis News 9.09 March 6, 2018 | |
 | |
| |
TOP STORYInvestigators showed that although the microRNA miR-126 supported the quiescence, self-renewal and engraftment capacity of chronic myelogenous leukemia (CML) leukemia stem cells (LSCs), miR-126 levels were lower in CML LSCs than in long-term hematopoietic stem cells from healthy individuals. [Nat Med] Abstract | Press Release | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development Researchers studied the cooperation between activated JAK3/STAT5 signaling and HOXA9 overexpression, two events identified as significantly co-occurring in T-cell acute lymphoblastic leukemia. [Cancer Discov] Abstract | Full Article The authors demonstrated that mice deficient in Sipa1, which encodes Rap1 GTPase-activating protein, rarely develop chronic myelogenous leukemia (CML) upon transfer of primary hematopoietic progenitor cells expressing Bcr-Abl, which cause lethal CML disease in wild-type mice. Resistance requires both T cells and nonhematopoietic cells. [Nat Commun] Full Article Hematopoietic Lineage Distribution and Evolutionary Dynamics of Clonal Hematopoiesis Using targeted sequencing, clonal hematopoiesis of indeterminate potential was identified in 121 out of 437 elderly individuals. Variant allele frequencies (VAFs) of 91 mutations were studied in six peripheral blood cell fractions. VAFs were significantly higher in monocytes, granulocytes, and NK-cells compared to B- or T cells. [Leukemia] Abstract Scientists engineered a mouse model carrying a different fluorescent marker on each chromosome 2, located inside the minimum deleted region occurring after radiation exposure and recognized as the first leukemogenic event. They report that following radiation exposure, more than half of asymptomatic CBA Sfpi1GFP/mCh mice presented with expanding clones of preleukemic hematopoietic cells harboring a hemizygous interstitial deletion of chromosome 2. [Leukemia] Abstract HIF1α Drives Chemokine Factor Pro-Tumoral Signaling Pathways in Acute Myeloid Leukemia Researchers showed that high constitutive expression of migration inhibitory factor (MIF) in acute myeloid leukemia (AML) blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1α and HIF2α, establish that hypoxia supports AML tumor proliferation through HIF1α signaling. [Oncogene] Abstract Genotoxicity of Tetrahydrofolic Acid to Hematopoietic Stem and Progenitor Cells Hematopoietic stem and progenitor cells showed genomic instability, reduced colony-forming capacity and increased frequency of cycling and apoptotic hematopoietic stem cells upon tetrahydrofolic acid exposure. [Cell Death Differ] Abstract Investigators demonstrated that miR221 regulates bone marrow retention of such B-cell precursors by targeting PTEN, thus enhancing PI3K signaling in response to the chemokine CXCL12. MiR221-enhanced PI3K signaling lead to increased expression of the anti-apoptotic protein Bcl2 and VLA4 integrin-mediated adhesion to VCAM1 in response to CXCL12 in vitro. [Eur J Immunol] Abstract Apatinib Exhibits Anti-Leukemia Activity in Preclinical Models of Acute Lymphoblastic Leukemia Researchers investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in acute lymphoblastic leukemia (ALL) cells. They showed that Apatinib significantly inhibited cell growth and promoted apoptosis in both B and T lineage ALL cell lines in a dose- and time-dependent manner. [J Transl Med] Full Article CLINICAL RESEARCHResearchers utilized a third generation of anti-CD19 chimeric antigen receptor (CAR) T cell vector, which contains the Toll/interleukin-1 receptor domain of Toll-like receptor 2, to generate 1928zT2 T cells targeting CD19, and evaluated the efficacy of 1928zT2 T cells in relapse or refractory B cell acute lymphocytic leukemia patients with extramedullary involvement. [J Hematol Oncol] Full Article | |
| |
| |
REVIEWSStretching the Limits: From Homeostasis to Stem Cell Plasticity in Wound Healing and Cancer Researchers delineate the multifactorial determinants and general principles underlying the remarkable facets of stem cell plasticity, which lend promise for regenerative medicine and cancer therapeutics. [Nat Rev Genet] Abstract The authors present an overview of the challenges of cell reprogramming protocols with regard to hematopoietic stem cell generation from induced pluripotent stem cells, and highlight the potential role of miRNAs in cell reprogramming and in the differentiation of induced pluripotent stem cells. [J Cell Sci] Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSThe California Institute for Regenerative Medicine board awarded $5.74 million to City of Hope to fund a Phase I clinical trial testing a novel blood stem cell transplantation procedure for adult patients with severe sickle cell disease. [City of Hope (Business Wire, Inc.)] Press Release NIH Awards $4.6 Million for Chronic Pain Research The University of Illinois at Chicago has been awarded a $4.6 million grant from the National Heart, Lung, and Blood Institute to study the molecular neurobiology of chronic pain in patients with sickle cell disease and to develop potential new drug treatments. [University of Illinois at Chicago] Press Release GlycoMimetics Announces Design of Phase III Clinical Trial for GMI-1271 in Relapsed/Refractory AML GlycoMimetics, Inc. announced its design for a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate GMI-1271 in combination with mitoxantrone, etoposide and Ara-C or in combination with fludarabine, cytosine arabinoside and idarubicin in individuals with relapsed/refractory acute myeloid leukemia (AML). [GlycoMimetics, Inc.] Press Release Trovagene, Inc. announced that the initial patient successfully completed the first cycle 1 of treatment in its Phase Ib/II multicenter trial of PCM-075 in combination with lLDAC in patients with Acute Myeloid Leukemia (AML). [Trovagene, Inc.] Press Release Gale and Ira Drukier Prize in Children’s Health Research Awarded to Harvard Hematologist Dr. Vijay Sankaran, a physician-scientist who investigates the molecular underpinnings of pediatric genetic blood disorders, has been awarded the third annual Gale and Ira Drukier Prize in Children’s Health Research, Weill Cornell Medicine announced. [Weill Cornell Medicine (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSNew NSF Rules on Sexual Harassment Leave Many Questions Unanswered The National Science Foundation (NSF) in Alexandria, Virginia, hopes that its new policy on sexual harassment will spur universities to deal more aggressively with the pervasive problem. But the additional reporting requirements, which will be officially published in the Federal Register, are far from a definitive statement about how NSF plans to deal with this complex and sensitive subject. [ScienceInsider] Editorial EU Research Chief’s Next Act: Changing the Future of Academic Publishing Robert-Jan Smits, one of Europe’s most powerful figures in research, has been appointed as a special envoy on open science at the European Commission, to help push efforts to make all publicly funded research in Europe freely available by 2020. [Science|Business] Editorial Here’s How the Scientists Running for Office Are Doing They’re trained problem-solvers, but they have to learn to move beyond data to run successful campaigns. [The Atlantic] Editorial Canadian Science Wins Billions in New Budget Canadian Prime Minister Justin Trudeau’s administration released its 2018 budget and scientists couldn’t be happier. It includes almost CAD 4 billion (USD 3.1 billion) in new funding for science over the next five years, a significant portion of which will go to the country’s three granting councils. [Nature News] Editorial
| |
EVENTSNEW Gordon Research Conferences: Cell Death Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Associate – Stem Cell Biology and Cancer Epigenetics (The Jackson Laboratory) NEW Postdoctoral Fellow – Stem Cells, Development & Cancer (Albert Einstein College of Medicine) NEW Postdoctoral Research Fellow – Hematopoiesis (Fred Hutchinson Cancer Research Center) Postdoctoral Positions – Hematopoietic Stem Cells (Memorial Sloan Kettering Cancer Center) Postdoctoral Scientist – Haematopoietic Stem Cell Biology (University of Oxford) Postdoctoral Associate – Stem Cell Biology (Duke University) Postdoctoral Fellowship – Functional Genomics of Human Hematopoiesis (Harvard Medical School) Postdoctoral Scholar – Leukemia (University of Southern California) Postdoctoral Positions – Translational Leukemia (NYU Langone School of Medicine) Postdoctoral Research Associate – Mechanisms of Leukemia (University of Virginia) Postdoctoral position – Myeloma (MD Anderson Cancer Center) Postdoctoral Position – Hematology and Cancer Biology (University of Florida) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
